SelectION

SelectION is a clinical-stage biopharmaceutical company focused on developing innovative peptide therapies for autoimmune diseases and certain cancer indications. The company utilizes a specialized technology platform that targets autoreactive, chronically activated T cells through the creation of selective peptide blockers for ion channels associated with these conditions. This approach aims to functionally inhibit and eliminate disease-related T cells while preserving the protective immune response. By optimizing target selectivity, SelectION seeks to develop therapeutics that offer significantly improved efficacy and safety profiles, ultimately providing healthcare institutions with effective treatment options for pain management and oncology.